Management of locally advanced bladder cancer

early vs deferred chemotherapy.

Samira Syed, Geoffrey R. Weiss

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Locally advanced bladder cancer is associated with a high risk of local recurrence and distant metastases. Clinical and pathologic variables have been useful in predicting outcome in patients with muscle-invasive bladder cancer. Recently, a number of molecular prognostic markers have been identified that help predict tumor aggressiveness, response to chemotherapy, and survival. Transitional cell carcinoma is a chemosensitive tumor. The early use of chemotherapy to reduce the risk of recurrence and improve survival has been the focus of many randomized clinical trials. Unfortunately, the majority of studies have failed to show a survival advantage for chemotherapy-treated patients. Well-designed prospective trials that target high-risk patients, defined by clinical, pathological, and molecular features, and incorporate new more tolerable chemotherapeutic agents are needed to clarify the benefit of early chemotherapy.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalWorld Journal of Urology
Volume20
Issue number3
StatePublished - Aug 2002

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Survival
Recurrence
Transitional Cell Carcinoma
Neoplasms
Randomized Controlled Trials
Neoplasm Metastasis
Muscles

ASJC Scopus subject areas

  • Urology

Cite this

Management of locally advanced bladder cancer : early vs deferred chemotherapy. / Syed, Samira; Weiss, Geoffrey R.

In: World Journal of Urology, Vol. 20, No. 3, 08.2002, p. 175-182.

Research output: Contribution to journalArticle

@article{f5e0df5a51ab4d379726ee30e68f2915,
title = "Management of locally advanced bladder cancer: early vs deferred chemotherapy.",
abstract = "Locally advanced bladder cancer is associated with a high risk of local recurrence and distant metastases. Clinical and pathologic variables have been useful in predicting outcome in patients with muscle-invasive bladder cancer. Recently, a number of molecular prognostic markers have been identified that help predict tumor aggressiveness, response to chemotherapy, and survival. Transitional cell carcinoma is a chemosensitive tumor. The early use of chemotherapy to reduce the risk of recurrence and improve survival has been the focus of many randomized clinical trials. Unfortunately, the majority of studies have failed to show a survival advantage for chemotherapy-treated patients. Well-designed prospective trials that target high-risk patients, defined by clinical, pathological, and molecular features, and incorporate new more tolerable chemotherapeutic agents are needed to clarify the benefit of early chemotherapy.",
author = "Samira Syed and Weiss, {Geoffrey R.}",
year = "2002",
month = "8",
language = "English (US)",
volume = "20",
pages = "175--182",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Management of locally advanced bladder cancer

T2 - early vs deferred chemotherapy.

AU - Syed, Samira

AU - Weiss, Geoffrey R.

PY - 2002/8

Y1 - 2002/8

N2 - Locally advanced bladder cancer is associated with a high risk of local recurrence and distant metastases. Clinical and pathologic variables have been useful in predicting outcome in patients with muscle-invasive bladder cancer. Recently, a number of molecular prognostic markers have been identified that help predict tumor aggressiveness, response to chemotherapy, and survival. Transitional cell carcinoma is a chemosensitive tumor. The early use of chemotherapy to reduce the risk of recurrence and improve survival has been the focus of many randomized clinical trials. Unfortunately, the majority of studies have failed to show a survival advantage for chemotherapy-treated patients. Well-designed prospective trials that target high-risk patients, defined by clinical, pathological, and molecular features, and incorporate new more tolerable chemotherapeutic agents are needed to clarify the benefit of early chemotherapy.

AB - Locally advanced bladder cancer is associated with a high risk of local recurrence and distant metastases. Clinical and pathologic variables have been useful in predicting outcome in patients with muscle-invasive bladder cancer. Recently, a number of molecular prognostic markers have been identified that help predict tumor aggressiveness, response to chemotherapy, and survival. Transitional cell carcinoma is a chemosensitive tumor. The early use of chemotherapy to reduce the risk of recurrence and improve survival has been the focus of many randomized clinical trials. Unfortunately, the majority of studies have failed to show a survival advantage for chemotherapy-treated patients. Well-designed prospective trials that target high-risk patients, defined by clinical, pathological, and molecular features, and incorporate new more tolerable chemotherapeutic agents are needed to clarify the benefit of early chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036674367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036674367&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 175

EP - 182

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -